Drug Trial Radar · NCT05480592
A Study of HS-10380 in Chinese Participants
Last checked: Nov 19, 2026Latest source record: Mar 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
76
Planned (sponsor's estimate)
Start
Aug 1, 2022
Primary completion
Jun 30, 2023
Study completion Jul 30, 2023
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the safety and tolerability of single and multiple oral administered doses of HS-10380 in Chinese healthy subjects.
Conditions
- Schizophrenia
Interventions
HS-10380Drug
Administered orally as a tablet
PlaceboDrug
Administered orally as a tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects Experiencing Adverse Events (AEs)Time frame: Baseline to end of follow-up (a maximum of 20 days)
- Changes from baseline in laboratory testsTime frame: Baseline to end of follow-up (a maximum of 20 days)
- Changes from baseline in vital signsTime frame: Baseline to end of follow-up (a maximum of 20 days)
- Change from baseline in Electrocardiogram (ECG)Time frame: Baseline to end of follow-up (a maximum of 20 days)
- Change from baseline in weight (kg)Time frame: Baseline to end of follow-up (a maximum of 20 days)
- Change from baseline in physical examinationTime frame: Baseline to end of follow-up (a maximum of 20 days)
- Change from baseline in Simpson-Angus Scale (SAS) scoreTime frame: Baseline to end of follow-up (a maximum of 20 days)
- Change from baseline in Abnormal Involuntary Movement Scale (AIMS) scoreTime frame: Baseline to end of follow-up (a maximum of 20 days)
- Change from baseline in Barnes Akathisia Rating Scale (BARS) scoreTime frame: Baseline to end of follow-up (a maximum of 20 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.